i
Cancer Risk Following ABO Incompatible Living Donor Kidney Transplantation (1)
-
Sep 15 2013
Source: Transplantation. 96(5):476-479. -
Alternative Title:Transplantation
-
Personal Author:
-
Description:Background
Recipients of ABO incompatible (ABOi) living donor kidney transplants often undergo more intense immunosuppression than their ABO compatible (ABOc) counterparts. It is unknown if this difference leads to higher cancer risk after transplantation. Single-center studies are too small, and lack adequate duration of follow-up, to answer this question.
Methods
We identified 318 ABOi recipients in the Cancer Transplant Match Study, a national linkage between the Scientific Registry of Transplant Recipients and population-based U.S. cancer registries. Seven cancers (non-Hodgkin lymphoma, Merkel cell carcinoma, gastric adenocarcinoma, hepatocellular carcinoma, thyroid cancer, pancreatic cancer, and testicular cancer) were identified among ABOi recipients. We then matched ABOi recipients to ABOc controls by age, gender, race, HLA mismatch, retransplantation, and transplant year.
Results
There was no demonstrable association between ABOi and cancer in unadjusted incidence rate ratio (IRR 0.83, 95% CI 0.33–1.71, p=0.3) or matched control analysis (IRR 0.99, 95% CI 0.38–2.23, p=0.5).
Conclusion
To the extent that could be determined in this registry study, current desensitization protocols are not associated with increased risk of cancer after transplantation.
-
Subjects:
-
Source:
-
Pubmed ID:23799426
-
Pubmed Central ID:PMC3759597
-
Document Type:
-
Funding:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: